Who is on it, and how far along Every drug ChEMBL records acting on this target, by the furthest stage it has reached for any use, coloured by modality.
How to read this Each mark is one drug. Columns run from approved to phase 1; hover or tap a mark for its sponsor, modality and open trials, and click it to open the drug.
Approved3 Dinutuximab Dinutuximab SponsorUnited Therapeutics ModalityAntibody ActionBinding agent Open trials28 Dinutuximab beta Dinutuximab beta SponsorBeOne Medicines ModalityAntibody ActionInhibitor Open trials20 Naxitamab Naxitamab SponsorY-mAbs Therapeutics ModalityAntibody ActionBinding agent Open trials17 Phase 23 4B5 4B5 SponsorAstraZeneca Pharmaceuticals ModalityOther ActionOther Open trials5 BIW-8962 BIW-8962 SponsorKyowa Kirin ModalityOther ActionInhibitor Open trials0 EMD-273063 EMD-273063 SponsorNot known ModalityOther ActionOther Open trials0 Phase 12 14G2A 14G2A SponsorNot known ModalityOther ActionInhibitor Open trials1 MORAB-028 MORAB-028 SponsorMorphotek ModalityOther ActionCross-linking agent Open trials0
Every drug acting on it, furthest along first. The sponsor is the US application holder where there is one, else the industry lead sponsor of most of its registered trials. The most recently posted recruiting or ongoing trials naming each drug (up to 8 a drug), 24 in all, from ClinicalTrials.gov. Trial Drug Phase Status Lead sponsor First posted Naxitamab Enabled Transplant-Free Study in High-Risk Neuroblastoma Dinutuximab, Naxitamab, Dinutuximab beta Phase 2 Recruiting Giselle Sholler Nov 12, 2026 Phase I/II Trial of Dinutuximab Beta in Combination With Irinotecan and Rapamycin in Pediatric, Adolescents and Adult Patients With Relapsed/Refractory Bone Tumors. Dinutuximab, Dinutuximab beta Phase 1 / Phase 2 Not yet recruiting University Hospital, Strasbourg, France Oct 1, 2026 Dinutuximab-beta and Chemotherapy in Newly Diagnosed High-Risk Neuroblastoma Dinutuximab, Dinutuximab beta Phase 1 Recruiting Chang Gung Memorial Hospital Jul 7, 2026 Patients Between the Ages of 12 Months to 21 Years With Newly-Diagnosed High-Risk Neuroblastoma Will Receive Children's Oncology Group (COG) Type Recommended Therapy With the Addition of Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) to Induction Cycles 1-5 Naxitamab Phase 2 Recruiting Shaare Zedek Medical Center Apr 17, 2026 Testing the Addition of Iberdomide to Therapy in People With Neuroblastoma That Has Come Back, Not Responded to Treatment, or Gotten Worse Dinutuximab, Dinutuximab beta Phase 1 / Phase 2 Recruiting National Cancer Institute (NCI) Feb 27, 2026 Chemoimmunotherapy Combined With Autologous NK Cell Therapy for Pediatric Patients With Refractory and Relapsed High-Risk Neuroblastoma and Ganglioneuroblastoma Dinutuximab, Dinutuximab beta Phase 3 Recruiting Federal Research Institute of Pediatric Hematology, Oncology and Immunology Jan 29, 2026 A Multi-Arm, Platform Trial For Relapsed Neuroblastoma Dinutuximab, Dinutuximab beta Phase 1 / Phase 2 Recruiting University of Birmingham Jan 12, 2026 Phase II Study of Chidamide-Dinutuximab Beta-Irinotecan-Temozolomide for Refractory/Relapsed Neuroblastoma in Children Dinutuximab, Dinutuximab beta Phase 2 Recruiting Tianjin Medical University Cancer Institute and Hospital Jan 6, 2026 NANT 2021-02: Randomized MIBG With Vorinostat/Dinutuximab/Vorinostat + Dinutuximab Dinutuximab Phase 2 Not yet recruiting New Approaches to Neuroblastoma Therapy Consortium Dec 3, 2025 GYNGHER - HER2 Expression in Gynecological Malignancies: a Brazilian Cohort 4B5 — Recruiting AstraZeneca Aug 3, 2025 Feasibility Study of Prolonged Administration of Naxitamab, Irinotecan, and Temozolomide for Patients With Relapsed or Refractory Neuroblastoma Naxitamab Phase 1 Recruiting Steven DuBois, MD Jun 18, 2025 Study of Naxitamab and Sacituzumab Govitecan in Patients With Metastatic Triple-negative Breast Cancer (TNBC) Naxitamab Phase 1 / Phase 2 Recruiting M.D. Anderson Cancer Center Jun 9, 2025 International Phase I Trial of Dinutuximab Beta With VDC/IE in GD2-Positive Ewing Sarkoma Dinutuximab beta Phase 1 Recruiting Prof. Dr. Dr. Birgit Burkhardt Feb 21, 2025 Prognostic Value of a Multidimensional Assessment for Survival in Elderly Patients With CKD 4B/5 4B5 — Not yet recruiting Centre Hospitalier Universitaire de Besancon Feb 13, 2025 Adding Of Naxitamb In Induction Therapy For High Risk Neuroblastoma Naxitamab — Recruiting Guangzhou Women and Children's Medical Center Aug 28, 2024 Tipifarnib and Naxitamab for Relapsed/Refractory Neuroblastoma Naxitamab Phase 2 Recruiting Giselle Sholler Aug 7, 2024 N10: A Study of Reduced Chemotherapy and Monoclonal Antibody (mAb)-Based Therapy in Children With Neuroblastoma Naxitamab Phase 2 Recruiting Memorial Sloan Kettering Cancer Center Jul 30, 2024 Comparison of Molecular-Genetic Concordance of the Primary Tumor and Brain Metastases of Colorectal Cancer 4B5 — Recruiting Blokhin's Russian Cancer Research Center Jun 10, 2024 Pembrolizumab, Lenvatinib and IL-15 Superagonist N-803 in Combination With HER2 Targeting Autologous Dendritic Cell (AdHER2DC) Vaccine in Participants With Advanced or Metastatic Endometrial Cancer 4B5 Phase 1 / Phase 2 Recruiting National Cancer Institute (NCI) Feb 12, 2024 Naxitamab and Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) Combined With Isotretinoin for Maintenance Treatment of Patients With High-Risk Neuroblastoma in First Complete Response. Naxitamab Phase 4 Not yet recruiting SciClone Pharmaceuticals Sep 21, 2023 Gemcitabine and Ex Vivo Expanded Allogenic Universal Donor, TGFβi Natural Killer (NK) Cells With or Without Naxitamab (Danyelza) for the Treatment of Patients With Metastatic, GD2 Expressing, HER2 Negative Breast Cancer ANTI-GD2 monoclonal antibody 3F8 Phase 1 / Phase 2 Recruiting Margaret Gatti-Mays Sep 7, 2023 GD2 CAR T Cells in Diffuse Intrinsic Pontine Gliomas (DIPG) & Spinal Diffuse Midline Glioma(DMG) 14G2A Phase 1 Recruiting Stanford University Dec 12, 2019 The Effect in Wedge Resection and IVb/V Resection of the Liver for Gallbladder Cancer 4B5 Not applicable Recruiting Saint Vincent's Hospital, Korea Sep 30, 2016 Humanized Monoclonal Antibody 3F8 (Hu3F8) With Granulocyte-Macrophage Colony Stimulating Factor (GM-CSF) in the Treatment of Recurrent Osteosarcoma ANTI-GD2 monoclonal antibody 3F8 Phase 2 Active, not recruiting Memorial Sloan Kettering Cancer Center Jul 20, 2015
Show all 24Drugs, mechanisms, furthest stage (max phase) and modality (molecule type) are from ChEMBL CHEMBL3390823 , ChEMBL 37, fetched 2026-11-18 (CC BY-SA 3.0). Sponsors are the US application holder (Drugs@FDA) for approved drugs with a US page, else the industry lead sponsor of the most of the drug's ClinicalTrials.gov trials. Open trials are recruiting or ongoing studies naming the drug as an intervention on ClinicalTrials.gov , checked daily; this page as of 2026-11-22. ChEMBL and Open Targets